CO5700775A2 - Nuevos derivados triciclicos como antagonistas de ltd4 - Google Patents

Nuevos derivados triciclicos como antagonistas de ltd4

Info

Publication number
CO5700775A2
CO5700775A2 CO05056627A CO05056627A CO5700775A2 CO 5700775 A2 CO5700775 A2 CO 5700775A2 CO 05056627 A CO05056627 A CO 05056627A CO 05056627 A CO05056627 A CO 05056627A CO 5700775 A2 CO5700775 A2 CO 5700775A2
Authority
CO
Colombia
Prior art keywords
ltd4
antagonists
derivatives
compounds
new tricycle
Prior art date
Application number
CO05056627A
Other languages
English (en)
Inventor
Carlos Puig Duran
Tana Jordi Bach
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32309630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5700775(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of CO5700775A2 publication Critical patent/CO5700775A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Paints Or Removers (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

1.- Un compuesto de fórmula (I):o sus sales farmacéuticamente aceptables en las que:de uno a tres de A1, A2, A3 y A4 son átomos de nitrógeno, siendo los otros grupos -CR1-;G1 representa un grupo seleccionado de -CH2-O-, -CH2CH2-, -CH=CH-, -CH2-S-, -N(alquil C1-C4)-CH2;G2 representa un grupo seleccionado de -O-CH2-, -CH=CH-, -CH2-CH2-;R1, R2, R3 y R4, son iguales o diferentes y se seleccionan de átomos de hidrógeno o halógeno y grupos hidroxi, alquilo, alquenilo, alquinilo, alcoxi, alquiltio, amino, monoalquilamino, dialquilamino, nitro, ciano, aciloxi, alcoxicarbonilo, hidroxicarbonilo o acilamino, estando las cadenas hidrocarbonadas de estos grupos opcionalmente sustituidas con uno o más sustituyentes seleccionados de halógeno, grupos hidroxi, oxo, alcoxi, alquiltio, acilamino, fenilo, alcoxicarbonilo, amino, monoalquilamino, dialquilamino e hidroxicarbonilo,n, m y p son independientemente 0, 1 ó 2,Y representa un resto opcionalmente sustituido seleccionado de alquilo,-cicloalquilo, arilo, alquil-cicloalquilo, cicloalquil-alquilo, arilalquilo, alquilarilo, alquil-cicloalquil-alquilo, cicloalquil-alquil-cicloalquilo, alquil-aril-alquilo y aril-alquil-arilo, Z representa un grupo tetrazolilo, un grupo -COOR5, un grupo -CONR5R5, un grupo NHSO2R5 o un grupo -CONHSO2R5, en los que R5 representa un hidrógeno o un grupo alquilo, arilo, cicloalquilo, heterociclilo o heteroarilo opcionalmente sustituido.2.- Un compuesto de acuerdo con la reivindicación 1, en el que uno de A1, A2, A3 y A4 es un átomo de nitrógeno, siendo los otros grupos -CR1-.3.- Un compuesto de acuerdo con la reivindicación 2, en el que A1 es un átomo de nitrógeno y A2, A3 y A4 son grupos -CR1-.4.- Un compuesto de acuerdo con la reivindicación 3, en el que R1 es un átomo de hidrógeno.
CO05056627A 2002-11-12 2005-06-10 Nuevos derivados triciclicos como antagonistas de ltd4 CO5700775A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200202590A ES2211315B1 (es) 2002-11-12 2002-11-12 Nuevos compuestos triciclicos.

Publications (1)

Publication Number Publication Date
CO5700775A2 true CO5700775A2 (es) 2006-11-30

Family

ID=32309630

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05056627A CO5700775A2 (es) 2002-11-12 2005-06-10 Nuevos derivados triciclicos como antagonistas de ltd4

Country Status (19)

Country Link
US (1) US7557212B2 (es)
EP (1) EP1560834B1 (es)
JP (1) JP2006508116A (es)
KR (1) KR20050074605A (es)
CN (1) CN100379742C (es)
AT (1) ATE399170T1 (es)
AU (1) AU2003288032A1 (es)
BR (1) BR0315462A (es)
CA (1) CA2505491A1 (es)
CO (1) CO5700775A2 (es)
DE (1) DE60321810D1 (es)
EC (1) ECSP055844A (es)
ES (2) ES2211315B1 (es)
MX (1) MXPA05005017A (es)
NO (1) NO20052858L (es)
RU (1) RU2330855C2 (es)
UA (1) UA80996C2 (es)
WO (1) WO2004043966A1 (es)
ZA (1) ZA200503806B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
PL1891974T3 (pl) 2004-05-31 2010-12-31 Almirall Sa Kombinacje zawierające środki przeciwmuskarynowe i inhibitory PDE4
US7550478B2 (en) 2005-06-23 2009-06-23 Merck & Co. Inc. Tyrosine kinase inhibitors
CA2624656A1 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Tyrosine kinase inhibitors
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
KR20140108627A (ko) 2011-07-26 2014-09-12 썬 파마 어드밴스트 리서치 컴패니 리미티드 퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)
JP2019081709A (ja) * 2016-03-18 2019-05-30 石原産業株式会社 有害生物防除剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68916699T2 (de) * 1988-04-28 1994-12-01 Schering Corp Benzopyridopiperidin, -piperidyliden und -piperazin-Verbindungen, Zusammensetzungen, Methoden zur Herstellung und Verwendung.
NZ234883A (en) * 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
DE69428783T2 (de) * 1993-02-16 2002-07-18 Ube Industries Quinolin-derivate
AU2230101A (en) * 1999-12-28 2001-07-09 Ube Industries, Ltd. Tricyclic compounds
JP2006151809A (ja) * 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物

Also Published As

Publication number Publication date
CA2505491A1 (en) 2004-05-27
EP1560834B1 (en) 2008-06-25
RU2005118757A (ru) 2006-02-27
MXPA05005017A (es) 2005-08-03
NO20052858L (no) 2005-08-12
ES2211315A1 (es) 2004-07-01
WO2004043966A1 (en) 2004-05-27
UA80996C2 (en) 2007-11-26
ECSP055844A (es) 2005-09-20
US7557212B2 (en) 2009-07-07
JP2006508116A (ja) 2006-03-09
ATE399170T1 (de) 2008-07-15
ES2211315B1 (es) 2005-10-16
CN1735618A (zh) 2006-02-15
EP1560834A1 (en) 2005-08-10
US20060116363A1 (en) 2006-06-01
DE60321810D1 (de) 2008-08-07
ZA200503806B (en) 2006-08-30
KR20050074605A (ko) 2005-07-18
AU2003288032A1 (en) 2004-06-03
NO20052858D0 (no) 2005-06-13
CN100379742C (zh) 2008-04-09
BR0315462A (pt) 2005-08-23
ES2306906T3 (es) 2008-11-16
RU2330855C2 (ru) 2008-08-10

Similar Documents

Publication Publication Date Title
CO5700775A2 (es) Nuevos derivados triciclicos como antagonistas de ltd4
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
MX2007000036A (es) Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
EA200700902A1 (ru) 3-ариламинопиридиновые производные
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ATE388708T1 (de) Piperazinderivate und anwendungsverfahren
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
NO20070878L (no) Dimere piperidinderivater
BRPI0413982A (pt) derivados de alfa-aminoamida úteis como agentes anti-inflamatórios
SG171472A1 (en) Substituted aniline derivatives
ATE553088T1 (de) Substituierte chinolone ii